Searchable abstracts of presentations at key conferences on calcified tissues

ba0006is12biog | (1) (1) | ICCBH2017

The ERNS as a tool for the European research on rare diseases

Sangiorgi Luca, on behalf of BOND ERN

Biographical DetailsM Kassim JavaidAfter completing medical training at Charing Cross and Westminster Medical School, I specialized in adult rheumatology at the Wessex Deanery. During that time, I completed a PhD examining the maternal determinants of intra-uterine bone growth as part of an ARC Clinical Fellowship at the University of Southampton fo...

ba0006is14biog | (1) (1) | ICCBH2017

Bone, body composition and metabolic abnormalities after allogeneic hematopoietic stem cell transplantation during childhood

Mostoufi-Moab Sogol

Biographical DetailsSogol Mostoufi-MoabI am an Assistant Professor of Pediatrics at the Children’s Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, and board certified in pediatric oncology and endocrinology. I have advanced epidemiology training and my research program is focused on bone, body composit...

ba0002is2biog | (1) (1) | ICCBH2013

Epigenetic influences on childhood bone accrual

Javaid Kassim

Biographical DetailsAfter completing medical training at Charing Cross and Westminster Medical School, I specialized in adult rheumatology at the Wessex Deanery. During that time, I completed a PhD examining the maternal determinants of intra-uterine bone growth as part of an ARC Clinical Fellowship at the University of Southampton. In my last year of clinical training, I was fortunate to...

ba0002p141 | (1) | ICCBH2013

Novel splicing mutation in FKBP10 gene in a patient with moderate/severe form of osteogenesis imperfecta

Venturi Giacomo , Gandini Alberto , Monti Elena , Corradi Massimiliano , Vincenzi Monica , Piona Claudia , Morandi Grazia , Pepaj Orsiol , Antoniazzi Franco

Background: Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized by bone fragility and osteopaenia, with a broad spectrum of clinical severity. The majority of cases are dominantly inherited and due to mutations in type I collagen genes, whereas recessive forms are less frequent and attributable to mutations in different genes involved in collagen I post translational modifications and folding (prolyl-3-hydroxylase complex, SERPINH1, FKBP1...

ba0004lb2 | (1) | ICCBH2015

Recessive osteogenesis imperfecta caused by missense mutations in SPARC

Mendoza Roberto , Fahiminiya Somayyeh , Majewski Jacek , Consortium Care4Rare Canada , Tetreault Martine , Nadaf Javad , Kannu Peter , Sochett Etienne , Howard Andrew , Stimec Jennifer , Dupuis Lucie , Roschger Paul , Klaushofer Klaus , Palomo Telma , Ouellet Jean , Al-Jallad Hadil , Mort John , Moffatt Pierre , Boudko Sergei , Bachinger Hans-Peter , Rauch Frank

Objectives: We sought to identify the disease-causing mutations in two unrelated girls with a clinical diagnosis of osteogenesis imperfecta type IV.Methods: Whole-exome sequencing and cellular studies in skin fibroblasts were conducted.Results: We identified two homozygous variants in SPARC (NM_003118.3; c.497G>A (p.Arg166His) in individual 1; c.787G>A (p.Glu263Lys) in individual 2). Secreted protein, acidic, cyste...

ba0003pp6 | Arthritis and other joint diseases: translational and clinical | ECTS2014

MIV-711, a highly selective cathepsin K inhibitor: safety, pharmacokinetics and pharmacodynamics of multiple oral doses in healthy postmenopausal women

Grabowska Urszula , Lindstrom Erik , Jerling Markus , Edenius Charlotte

Introduction: Cathepsin K is necessary for bone matrix resorption. Excessive resorption associated with osteoporosis and osteoarthritis can be reduced by cathepsin K inhibition. MIV-711, a highly selective cathepsin K inhibitor, successfully attenuates both bone resorption and cartilage degradation in non-clinical studies.Aim: To determine safety, tolerability, pharmacokinetics and pharmacodynamics of MIV-711 during multiple oral dosing to postmenopausal...

ba0001pp430 | Osteoporosis: treatment | ECTS2013

First in man study of a novel and highly selective cathepsin K inhibitor miv-711 – safety, pharmacokinetics and pharmacodynamics of single ascending oral doses in healthy subjects

Grabowska Urszula , Lindstrom Erik , Jerling Markus , Larsson Torbjorn , Bottiger Disa , Danielson Kerstin , Kristensen Jens D , Edenius Charlotte

Aim: To determine the safety, tolerability, pharmacokinetics and pharmacodynamics of the cathepsin K inhibitor MIV-711.Methods: A double-blind, placebo-controlled, randomized study in 27 healthy subjects of both genders. Single ascending doses 20–600 mg were investigated for adverse events, clinical chemistry, vital signs, ECG parameters, pharmacokinetics, and serum levels of CTX-I.Results: MIV-711 was well tolerated with no a...

ba0002is7 | (1) (1) | ICCBH2013

Osteogenesis imperfecta

Pals Gerard

Osteogenesis imperfecta (OI) is a genetic disorder, leading to fragility of the bones. The clinical variability is extreme, ranging from relatively mild to perinatally lethal. Secondary features such as short stature, blue sclerae, dentinogenesis imperfecta and hearing loss may also exist in affected individuals. OI is most often caused by mutations in the collagen type I genes COL1A1 and COL1A2, that show a dominant mode of inheritance. The least severe OI c...

ba0005p3 | Arthritis and other joint diseases: translational and clinical | ECTS2016

The influence of secondary hyperparathyroidism -at the time of index operation- on the later development of (septic or aseptic) loosening of implants in female patients with knee osteoarthritis who undergo total knee arthroplasty

Papavasiliou Kyriakos , Michael Theodore , Tsitouras Dimosthenis , Karanassos Marinos , Adam Stergios , Kirkos John

Objectives: Prospective case-controlled study assessing whether the incidence of loosening of implants in patients undergoing Total Knee Arthroplasty (TKA) is higher among those with Secondary Hyperparathyroidism (SP) at the time of index operation.Material and methods: Caucasian female patients with knee osteoarthritis who underwent TKA between November 2004 and March 2007 were enrolled. Exclusion criteria: endocrinopathies, rheumatoid or secondary arth...

ba0006p085 | (1) | ICCBH2017

Cumulative radiation exposure from diagnostic imaging and associated lifetime cancer risk in children with Osteogenesis Imperfecta

Thorby-Lister Amy , Hogler Wolfgang , Hodgson Kirsten , Crabtree Nicola , Shaw Nick , Saraff Vrinda

Background and objectives: Fracture rate in Osteogenesis Imperfecta (OI) is highest between 0 and 19 years, and associated radiation exposure also carries the highest lifetime cancer risk. Here, we investigate the cumulative effective radiation dose (E) and lifetime cancer risk from diagnostic imaging in OI children. We also explore the hypothesis that negative family history of OI will increase injury-related, fracture-negative X-rays due to parental anxiety.<p class="abs...